ADAMTS-13 Activity with Inhibitor Screen (Blood)

Testing Laboratory

Department

Haematology

Delphic Registration Code (Alpha Code)

TS13

Test Code (Numeric Code)

1365

Laboratory Handling

Phlebotomy

Synonyms

ADAMTS-13 Level
ADAMTS-13

Turnaround Time

3 days

Requests for ADAMTS-13 activity must be arranged through a LabPlus Haematologist who will also advise when results will be available. Please note the assay takes 5 hours to complete.

Specimen Type

• Whole Blood

Specimen Requirements

Tube/Container Type:

Preferred

• Citrate (Blue Cap)

Preferred Sample Volume (ml)

2.7

Paediatric Specimen Requirements

Tube/Container Type:

Preferred

• Citrate (Microtainer)
• Please refer to Additional Information below

Minimum Sample Volume (ml)

2

Pre-testing Requirements

Requests for this test must be arranged by contacting a LabPLUS Haematologist.
If requests are received with no prior discussion they will not be processed.
Please provide requestor contact phone details on the request form.

Additional Specimen Information

Paediatric: collect 2 x 1ml Citrate microtainer.
1. EDTA destroys ADAMTS-13 activity, so it is important to collect/fill citrate specimen(s) before EDTA specimens to avoid EDTA contamination.
2. Collection tubes must be adequately filled.

Aliquot Instructions

Sample Type

• Plasma

Transport to Lab

Frozen

Additional Referral/Aliquot Information

Double spin plasma before freezing in 1 ml aliquots.
To ensure the plasma is platelet poor before freezing double spin plasma as follows: transfer the plasma after the initial centrifugation to a suitable plastic tube using a plastic transfer pipette then re-centrifuge. When aliquoting from the second spin tube into the final tube take care to avoid the bottom 0.5 cm where residual platelets are deposited. Identify double spun aliquots by noting this on the label.
Haemolysed specimens may be unsuitable for testing.

Test Method

As from October 2017 ADAMTS-13 Activity is determined by an ELISA chromogenic test at Labplus.
The ADAMTS-13 activity is reported together with an ADAMTS-13 inhibitor screen for timely distinction between congenital and acquired deficiency.

Uncertainty of Measurement

Contact Information